
1. General Information
LENVITIB 10 mg Capsules contain lenvatinib, a kinase inhibitor used in the treatment of certain types of cancer. Lenvatinib works by blocking specific signaling pathways involved in blood-vessel formation and tumor growth. It is used under specialist medical supervision and is available as an oral capsule.
Phoenix Exim is a pharmaceutical exporter based in Nagpur, India, supplying pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea, and UAE, subject to applicable import regulations.
2. Product Information
- Product: LENVITIB 10 mg Capsules
- Active Ingredient: Lenvatinib
- Strength: 10 mg
- Dosage Form: Hard capsule
- Route: Oral
- Therapeutic Category: Anticancer / kinase inhibitor
- ATC Code: L01XE29
- Prescription Status: Prescription-only medicine
- Storage: Store according to the manufacturer's labeled storage instructions.
A 10 mg Lenvima capsule contains lenvatinib equivalent to 10 mg; the capsule formulation contains lenvatinib mesylate equivalent to the stated lenvatinib strength.
3. Uses of LENVITIB 10 mg
Lenvatinib is used for certain cancer indications, including:
- Differentiated thyroid cancer (DTC) that is progressive, locally recurrent or metastatic and refractory to radioactive iodine.
- Advanced renal cell carcinoma (RCC) in combination with pembrolizumab as first-line treatment.
- Advanced RCC in combination with everolimus following previous anti-angiogenic therapy.
- Unresectable hepatocellular carcinoma (HCC) as first-line treatment.
- Certain cases of advanced endometrial carcinoma, in combination with pembrolizumab, when specified tumor characteristics and prior-treatment criteria are met.
4. Benefits of This Medicine
When prescribed appropriately, lenvatinib may:
- Help slow the growth and progression of certain cancers.
- Inhibit the formation of new blood vessels that tumors need for growth.
- Provide an oral treatment option for eligible cancer patients.
- Be used alone or in combination with other anticancer medicines depending on the cancer type.
The expected benefit varies according to the cancer type, disease stage, previous treatment and the individual patient's condition.
5. Side Effects of LENVITIB 10 mg
Lenvatinib can cause side effects, and some may be serious. Important risks include:
- High blood pressure
- Heart problems
- Arterial or venous blood clots
- Liver problems
- Kidney problems and proteinuria
- Severe bleeding
- Gastrointestinal perforation or fistula
- QT-interval prolongation
- Wound-healing complications
- Reversible posterior leukoencephalopathy syndrome
- Thyroid dysfunction
Patients should contact their healthcare professional promptly if they develop severe or unusual symptoms.
6. Common Side Effects
Common adverse effects can include:
- Fatigue
- Diarrhea
- Nausea
- Vomiting
- Decreased appetite
- Weight loss
- Headache
- High blood pressure
- Abdominal pain
- Stomatitis or mouth inflammation
- Muscle or joint pain
- Proteinuria
- Rash
- Palmar-plantar erythrodysesthesia (hand-foot syndrome)
- Voice changes
- Hypothyroidism in some treatment combinations
The frequency of individual side effects varies depending on the cancer being treated and whether lenvatinib is used alone or with another medicine.
7. How to Use LENVITIB 10 mg
LENVITIB should be taken exactly as prescribed by an oncologist. The appropriate dose is not determined simply by the capsule strength; recommended regimens vary according to the indication and may require dose modifications.
The capsule is generally taken orally once daily, with or without food, at approximately the same time each day. Swallow capsules as directed by the prescribing healthcare professional. Do not change the dose or stop treatment without medical advice.
If a dose is missed or vomiting occurs after taking the medicine, follow the instructions provided by the treating healthcare professional or product information.
8. How LENVITIB Works
Lenvatinib is a multi-kinase inhibitor. It blocks several receptors involved in angiogenesis and tumor growth, particularly VEGFR1, VEGFR2 and VEGFR3. It also inhibits pathways involving FGFR1–4, PDGFRA, KIT and RET.
By interfering with these signaling pathways, lenvatinib can reduce the formation of new blood vessels that support tumor growth and can inhibit signaling involved in cancer-cell proliferation.
9. Safety Advice
- Use only under the supervision of a qualified healthcare professional.
- Blood pressure should be checked regularly because hypertension can be serious.
- Inform your doctor about existing heart, liver, kidney, bleeding or blood-pressure problems.
- Tell your doctor about all prescription medicines, supplements and other treatments you take.
- Your doctor may monitor blood pressure, thyroid function, kidney function, liver function and urine protein during treatment.
- Discuss pregnancy and breastfeeding with your healthcare professional before treatment.
- Seek urgent medical attention for severe chest pain, breathing difficulty, major bleeding, severe abdominal pain, neurological symptoms or other serious symptoms.
- Do not alter the prescribed dose without medical advice.
10. Frequently Asked Questions
Q1. What is LENVITIB 10 mg?
LENVITIB 10 mg contains lenvatinib, an oral kinase inhibitor used to treat certain cancers.
Q2. Is LENVITIB 10 mg a chemotherapy medicine?
It is an anticancer medicine, but it works differently from traditional cytotoxic chemotherapy. It is classified as a kinase inhibitor.
Q3. What cancers can lenvatinib treat?
Depending on the regulatory indication, it can be used for certain thyroid, kidney, liver and endometrial cancers.
Q4. Can LENVITIB 10 mg be taken without a prescription?
No. Lenvatinib is a prescription-only medicine and cancer treatment should be supervised by an experienced healthcare professional.
Q5. Is 10 mg the standard dose for every patient?
No. The recommended dose depends on the indication, treatment combination, kidney/liver function and individual tolerability.
Q6. Can LENVITIB be combined with other cancer medicines?
Yes. For certain indications it is specifically used with medicines such as pembrolizumab or everolimus.
Q7. What should I do if I experience side effects?
Contact your treating healthcare professional. Some adverse reactions require dose adjustment, interruption or additional treatment.
Q8. Is LENVITIB suitable for children?
Safety and effectiveness depend on the specific indication and population; the approved LENVIMA labeling does not establish general safety and effectiveness for children.
11. Substitute for LENVITIB 10 mg
Potential alternatives or substitutes cannot be selected solely by strength. Depending on the cancer type and treatment plan, an oncologist may consider another lenvatinib product or a different targeted anticancer medicine.
Examples of medicines that may be considered in particular treatment settings include sorafenib, pazopanib, cabozantinib or other targeted therapies, but these are not automatically interchangeable with LENVITIB. The appropriate alternative must be selected by the treating oncologist based on diagnosis, treatment history, molecular characteristics and local treatment guidelines.
12. SEO Keywords
- LENVITIB 10 mg Capsules
- LENVITIB 10 mg exporter from India
- LENVITIB 10 mg pharmaceutical exporter
- Lenvatinib 10 mg Capsules supplier India
- Lenvatinib 10 mg medicine exporter
- Lenvatinib capsules supplier from Nagpur India
- Lenvatinib 10 mg wholesale supplier
- Lenvatinib 10 mg international supplier
- Lenvatinib 10 mg for thyroid cancer
- Lenvatinib 10 mg for kidney cancer
- Lenvatinib 10 mg for liver cancer
- Lenvatinib anticancer medicine supplier
- Lenvatinib oncology medicine exporter India
- LENVITIB 10 mg Capsules exporter USA
- LENVITIB 10 mg Capsules exporter UK
- LENVITIB 10 mg Capsules exporter Australia
- LENVITIB 10 mg Capsules exporter Singapore
- LENVITIB 10 mg Capsules exporter Canada
- LENVITIB 10 mg Capsules exporter South Korea
- LENVITIB 10 mg Capsules exporter UAE
- Lenvatinib 10 mg B2B pharmaceutical supplier
- Lenvatinib 10 mg bulk medicine supplier
- Lenvatinib 10 mg oncology product supplier India
- Phoenix Exim Lenvatinib supplier
- Phoenix Exim pharmaceutical exporter Nagpur India
Keywords







